CMS Ties Hyaluronidase SC Drugs to Originals

New Medicare negotiation rules group certain subcutaneous combination formulations with their original drugs, and Alteogen shares fell sharply in Seoul.

Updated on Nov. 9, 2026 in Healthcare

Photograph of an unlabeled amber glass vial beside a single prefilled syringe on a brushed steel tray, with a conveyor line softly blurred behind.
The U.S. Centers for Medicare & Medicaid Services finalized rules on November 6 that group certain hyaluronidase-based drugs with their original products for Medicare price negotiation, and Alteogen shares fell 15.71% in Seoul. AI Illustration. Upload story photo >

The U.S. Centers for Medicare & Medicaid Services finalized drug price negotiation regulations on November 6, 2026, grouping certain hyaluronidase-based subcutaneous combination formulations with their original drugs for negotiation eligibility. Alteogen, which holds the Hybrozyme platform, fell 15.71% on KOSDAQ on November 9.

Why it matters

Pharmaceutical companies had treated hyaluronidase-based subcutaneous formulations as separate combination drugs for negotiation purposes, a approach that could have delayed price negotiation. The rule change may limit that strategy, which the market appears to be weighing.

Alteogen traded at 169,000 Korean won at 9:43 AM on November 9, 2026, down 31,500 won or 15.71% from the previous session. The number of drugs affected by the grouping rule and its projected revenue impact were not disclosed in the source material.

The players

Centers for Medicare & Medicaid Services (CMS)

The federal agency that administers Medicare and Medicaid and issued the final drug price negotiation regulations.

Alteogen

A South Korean biopharmaceutical company whose Hybrozyme platform converts intravenous biologics into subcutaneous formulations.

The details

The regulations address hyaluronidase-based formulations, which reformulate intravenous biologics for subcutaneous delivery and reduce administration time. Under the new rule, such combinations are grouped with the original drug for price negotiation purposes rather than assessed separately.

Timeline

  1. November 6, 2026: CMS announced the final drug price negotiation regulations.

  2. November 9, 2026: Alteogen shares fell 15.71% on KOSDAQ during morning trading.

Market Landscape

The rule applies the Medicare drug price negotiation framework to hyaluronidase-based subcutaneous combinations, a formulation approach that had been used to position drugs differently for negotiation timing. Alteogen's sharp share decline reflects investor attention to whether such conversion strategies will keep their expected value under the final rules.

Patients receiving subcutaneous versions of biologic drugs may see those products handled under the same negotiation timeline as their original drugs. Pricing outcomes for individual medications will depend on how the negotiation process applies to each affected product.

The takeaway

Pharmaceutical strategies that rely on reformulation to shift regulatory timelines are subject to change as federal rules are finalized. Readers tracking drug costs should watch how CMS applies these groupings in practice.

Further reading

Explore more coverage in Healthcare for context on federal drug pricing policy.